Landmark Science announces research to be presented at ISPE 2025
LOS ANGELES, Aug. 19, 2025 /PRNewswire/ -- Landmark Science today announced its presence at International Society for Pharmacoepidemiology (ISPE) 2025 annual conference, in collaboration with Innovaccer, set to take place August 22–26 in Washington D.C. Landmark Science's real-world data is featured across five pieces of research to be presented at the conference.
The research provides a timely look into patient populations initiating GLP-1 receptor agonists (RAs), offering new insights into the characteristics of Medicare patients initiating these therapies. They also offer a special focus on Medicaid patients initiating Wegovy (semaglutide) for cardiometabolic and cardiovascular risk reduction — an area of growing importance as GLP-1 RAs expand beyond diabetes management.
"GLP-1s are on the rise in Medicare — from Type 2 diabetes and obesity to cardiovascular risk reduction, kidney disease, obstructive sleep apnea, and noncirrhotic MASH, indications for GLP-1s have expanded fast. But not a lot is known about utilization in a Medicare population. Real-world evidence is essential in understanding prescribing patterns, patient outcomes, and safety profiles, ultimately guiding optimal care strategies and policy decisions for Medicare beneficiaries," said Shivani Aggarwal, CEO.
"The rapid adoption of GLP-1s like semaglutide in cardiometabolic care highlights a critical need for real-world data to inform access, outcomes, and equity," said Puneet Budhiraja - Vice President, Analytics at Humbi AI by Innovaccer. "At ISPE, we're excited to share data that helps stakeholders better understand who is initiating these therapies — and who might be left behind."
At this year's ISPE, Landmark epidemiologists are also generating novel methodologies that will shape the future of evidence generation used to support regulatory decision-making. "Our research uncovers nuanced trends and synthesizes them into transparent, evidenced based research—to showcase and drive the utility of real-world evidence in regulatory decision-making," said Shivani Aggarwal.
Highlights include:
Two poster presentations on Medicare beneficiaries initiating GLP-1 RAs and Wegovy.
Two poster presentations underscoring RWE's potential for use in regulatory decision-making.
A poster presentation introducing a framework operationalizing regulatory guidelines into key steps for submission success.
Schedule a meeting with Landmark Science at ISPE 2025, and learn more about our abstracts and events, including workshops and panels.
Follow Landmark Science on LinkedIn for more updates from #ISPE2025.
Poster Discussions and Presentations
Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population
This study analyzes patient demographics, comorbidities, and outcomes among Medicare beneficiaries initiating any GLP-1 RAs, shedding light on the populations adopting these treatments.
- Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-032
Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population
Focusing specifically on Wegovy, this analysis offers a more granular view into who Wegovy initiators are, how they responded, and what happened after Wegovy became an option for cardiovascular protection.
- Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-033
Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs)
Real-world evidence use is growing but still has mixed acceptance. Here we synthesize emerging patterns into actionable insights for success.
- Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-079
Evaluation of Real-World Evidence in Regulatory and HTA Submissions
Real-world evidence isn't judged the same everywhere — and the differences matter. We review feedback from regulatory and key HTA bodies to describe the acceptability of RWE in marketing applications.
- Monday Aug 25, 2025 | Hall D | Poster Session B: 11:30 AM- 1:00 PM- Poster Code: B-080
Framework for Real-World Data Used in Regulatory Submissions
Discover our framework, which operationalizes regulatory guidelines about real-world data into key steps for submission readiness.
- Tuesday Aug 26, 2025 | Hall D | Poster Session C: 12:00 PM – 1:30 PM- Poster Code: C-124
About Landmark Science, Inc.Landmark Science, Inc. is a premier life science research organization providing real-world evidence and health outcomes research solutions. The company provides a comprehensive suite of services enabling the use of RWE to help patients. Landmark Science's team of experts deliver RWE for clinical program strategy, health economics, commercial, market access, regulators, and payors to meet diverse needs efficiently. Specialties include complex study designs used to support regulatory submissions, therapeutic area expertise, and data landscaping. To learn more, please visit www.landmarkscience.com or contact info@landmarkscience.com.
Media Contact:Landmark Sciencemedia@landmarkscience.com+1 (424) 535-3011https://landmarkscience.com/
View original content to download multimedia:https://www.prnewswire.com/news-releases/landmark-science-announces-research-to-be-presented-at-ispe-2025-302532655.html
SOURCE Landmark Science, Inc
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business of Fashion
2 hours ago
- Business of Fashion
Viking's GLP-1 Pill Results Mixed, Shares Slump
Viking Therapeutics said on Tuesday its experimental weight-loss pill helped people with obesity lose up to 12.2 percent of their body weight over 13 weeks in a keenly watched study. Yet, shares of the company slumped nearly 35 percent in premarket trading after data showed that more patients who received Viking's drug stopped taking the treatment, compared to those who received placebo in the mid-stage study. Oral drugs are expected to take a significant share of the projected $150 billion weight-loss market, driven by their ease of use compared with injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Viking's experimental oral pill is in a tight race with rival treatments being developed by the deeper-pocketed Novo and Lilly. Earlier this month, Eli Lilly said its experimental daily pill, orforglipron, showed a 12.4 percent weight loss in patients in a late-stage study over 72 weeks. In a separate trial, Novo's oral semaglutide has shown a weight loss of 15 percent over 68 weeks. Both the oral drugs are expected to be launched next year. Ahead of Viking's data, analysts expected weight loss in the range of 10 to 15 percent on average for the pill, known as VK2735. It had shown an 8.2 percent average weight-loss in a small early-stage trial. About 20 percent of those who received the drug discontinued due to an adverse effect, compared to 13 percent on placebo in the 280-patient study. The most common reasons for treatment discontinuation were gastrointestinal side effects, the company said. Like Lilly's Zepbound, Viking's drug also targets hormones known as GLP-1 and GIP that play a critical role in regulating the body's metabolism. Viking is testing both the oral and under-the-skin injection forms of the drug in overweight patients who have who at least one weight-related comorbidity. By Sriparna Roy and Siddhi Mahatole; Editors: Sriraj Kalluvila and Leroy Leo Learn more: GLP-1 Pills Will Be Priced Similarly to Injections, Wall Street Predicts US prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year will likely be on par with their weight-loss injections, analysts and investors say.
Yahoo
3 hours ago
- Yahoo
Global Mammography Equipment Market Accelerates with Smart Imaging Innovations
"AI-powered diagnostics, 3D imaging, and advanced techniques like CE DE Mammography and Molecular Breast Imaging are transforming breast cancer detection, driving demand for faster, safer, and more personalized screening solutions." BOSTON, Aug. 19, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Global Mammography Equipment Markets" is projected to grow from $3.1 billion in 2025 to $4 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030. This report provides a detailed review of the global mammography equipment market, highlighting current technologies, growth drivers, and emerging opportunities. The report segments by equipment type, end-user industry, and region. The analysis spans major global regions and countries, offering insights into market trends, ESG developments, patents, and technological innovations. It serves as a strategic resource for companies to understand procedural trends, brand perception, and competitive dynamics, helping them plan effectively and respond to potential market disruptions. The factors driving the market's growth include: Rising Global Incidence and Mortality of Breast Cancer: The growing number of breast cancer cases and related deaths worldwide is a major driver for mammography equipment. Early detection through screening is crucial for improving survival rates, which increases the demand for reliable and efficient diagnostic tools. Adoption of Mammography Screening: Due to heightened awareness, better healthcare access, and insurance coverage, more women are undergoing regular breast cancer screenings. This widespread adoption is fueling the need for advanced mammography systems in hospitals and clinics. Advances in AI Mammography and 3D Tomosynthesis: Innovations like 3D tomosynthesis and AI-enhanced imaging are making mammograms more accurate and efficient. These technologies help detect cancer earlier and reduce false positives, encouraging healthcare providers to upgrade their equipment. Development of Portable and Mobile Mammography Systems: To improve access in rural and underserved areas, manufacturers are creating portable and mobile mammography units. These systems support outreach programs and make screenings more accessible, expanding the market reach. Request a sample copy of the global market for mammography equipment report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $2.9 billion Market size forecast $4.0 billion Growth rate CAGR of 5.2% from 2025 to 2030 Segments covered Product Type and Sub-type, End User and Region Regions covered North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) Countries covered The U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Rest of Europe, China, India, Japan, Australia, Rest of Asia-Pacific Market drivers • Rising global incidence and mortality of breast cancer. • Increased adoption of mammography screening. • Advances in imaging technology, including AI-powered mammography and 3D tomosynthesis. • Government Initiatives and awareness campaigns. • Development of portable and mobile mammography systems Interesting facts: According to GLOBOCON 2024, female breast cancer ranks second in terms of new cancer cases globally, with 2,308,897 new cases, accounting for 11.6% of all cancer diagnoses. It ranks fourth in cancer-related deaths, with 665,684 deaths, representing 6.9% of all cancer mortality. Several AI-powered mammography solutions, like iCAD's ProFound AI and Hologic's Genius AI Detection 2.0, have already received FDA approval. These systems don't just assist radiologists — they independently flag suspicious areas, helping to increase cancer detection rates and reduce reading time by up to 50%. Emerging startups: Therapixel: Therapixel, a France- and U.S.-based startup, gained significant momentum between 2021 and 2024 with its FDA-approved AI solution, MammoScreen. The software supports radiologists by scoring mammograms and highlighting suspicious areas, helping to detect breast cancer earlier while reducing reading time. Therapixel's advances have made AI-assisted screening more practical and reliable in busy clinical environments. Vara: Based in Germany, Vara expanded its AI platform from 2021 to 2024 into new regions such as Mexico and India. Vara's technology is integrated directly into breast cancer screening workflows, assisting radiologists by pre-analyzing mammograms and flagging cases for review. The report addresses the following questions: 1. What are the projected market size and growth rate? The global market for mammography equipment was $2.9 billion in 2024. The market is expected to grow at a compound annual growth rate (CAGR) of 5.2%, reaching about $4.0 billion by 2030. 2. Which factors are driving the growth of the market? Key market drivers include the following:- Increasing adoption of mammography screening.- Advances in imaging technology, including AI-powered mammography and 3D tomosynthesis.- Government Initiatives and awareness campaigns.- Increasing adoption of mammography screening.- Development of advanced therapeutics. 3. Which market segments are covered in the report? The market is segmented by product type, end-user, and region. The market is segmented by product into an analog mammography system, a digital mammography system, a portable and mobile mammography system, and others. The digital mammography system market is further segmented by full-field mammography system(FFDM), digital breast tomosynthesis system (DBT) and contrast-enhanced mammography system (CEM). End users include hospitals, surgical, diagnostic, and breast care centers. The regions covered include North America, Europe, Asia-Pacific, and the Rest of the World, focusing on major countries in these regions, including the U.S., Canada, Mexico, Germany, the U.K., Italy, France, Spain, and the Rest of Europe, China, Japan, India, South Korea, and the Rest of Asia-Pacific. 4. Which type segment will be dominant through 2030? Digital mammography systems will dominate the market through the end of 2030. 5. Which region has the highest market share? North America holds the highest share of the market. 6. What are the challenges and opportunities in the market? The mammography equipment market faces several key challenges, including concerns over radiation safety and a global shortage of radiologists. For example, according to a 2022 article by the Radiological Society of North America, the U.K. has only 8.5 radiologists per 100,000 people, well below the European average of 13 per 100,000. However, the market also presents strong opportunities. The development of portable and mobile mammography systems, increasing healthcare spending in emerging markets, and advances in imaging technologies, such as AI-powered mammography and 3D tomosynthesis, are expected to drive future growth and improve access to breast cancer screening worldwide. Market leaders include: BMI BIOMEDICAL INTERNATIONAL S.R.L. CANON INC. FUJIFILM HOLDINGS CORP. GE HEALTHCARE GENORAY CO. LTD. HOLOGIC INC. ITALRAY KONINKLIJKE PHILIPS N.V. METALTRONICA S.P.A. PLANMED OY SCREEN POINT MEDICAL BV SIEMENS HEALTHINEERS AG SHANGHAI UNITED IMAGING HEALTHCARE CO. LTD. STERNMED GMBH VILLA SISTEMI MEDICALI SPA Related reports: Nanotechnology in Cancer Treatment: Technologies and Global Markets: This report offers a comprehensive analysis of the nanotechnology market in cancer treatment, focusing on product types (like liposomes and dendrimers) and cancer types (such as lung and breast cancer). It covers global and regional trends, market drivers, restraints, opportunities, and competitive dynamics. The report aims to assess market potential, regulatory scenarios, and long-term impacts, providing detailed forecasts and market share insights for major players across major regions. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
3 hours ago
- Forbes
Disappointing Obesity Pill Trial Results Cause Viking Therapeutics Shares To Crater
Shares of Viking Therapeutics plummeted more than 43% Tuesday after the company revealed poorer-than-expected mid-stage trial data for its experimental weight-loss pill, joining Eli Lilly with similar historic losses as pharmaceutical firms compete to develop an oral weight-loss drug. The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill. Getty Images Viking Therapeutics' shares dropped about 43% to just below $24 as of around 10:30 a.m. EDT, pacing what would be the company's largest single-day decline since the stock went public in May 2015 and marking a 69.5% drop from its 52-week high ($81.73) set in October 2024. Tuesday's stock plunge accounts for about $1.8 billion in losses for Viking Therapeutics, cutting the company's market capitalization by more than one-third to $2.8 billion. Viking Therapeutics earlier Tuesday reported mid-stage trial data for its weight-loss pill VK2735, which helped patients lose an average of 12.2% of their body weight after 13 weeks, compared to a 1.3% loss with a placebo. About 28% of patients discontinued VK2735 through the trial, however, with some patients reporting gastrointestinal side effects, including nausea and vomiting. The once-daily pill VK2735 had lower weight-loss results on average compared to Eli Lilly's orforglipron, which was tested over 72 weeks. The highest dose of Eli Lilly's once-daily treatment helped patients lose about 12.4% of their body weight in a late-stage trial, well below analyst expectations of 15%, according to FactSet. Those expectations appeared to trail Novo Nordisk's success: An oral version of its Wegovy treatment helped patients lose 15% of their body weight on average in a late-stage trial. Surprising Fact Eli Lilly's shares dropped more than 14% after reporting trial data for orforglipron on Aug. 7. That was the company's largest single-day loss since a 29% decrease on Aug. 8, 2000. Novo Nordisk shares increased more than 7% as a result. Viking Therapeutics emerged as a possible competitor in the growing weight-loss medication market in recent years as it develops an oral alternative. The company is also developing an injection, though both Viking Therapeutics and health experts have argued an oral weight-loss medication could greatly expand the market to more consumers. Novo Nordisk, whose Wegovy and Ozempic treatments have become increasingly popular, has its oral Wegovy treatment under regulatory review. A decision by the Food and Drug Administration is expected by late 2025. Other weight-loss pill trials have been abandoned: Pfizer's twice-daily danuglipron was dropped after testing suggested the drug could adversely affect the liver. Further Reading Forbes Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here's Why It's Down By Ty Roush
